Joseph Franciosa, MD
OwnerJoseph A. Franciosa, MD, Consultant
Joseph Franciosa, MD, is an Independent Consultant to the pharmaceutical and medical devices industry and is also an Adjunct Professor of Medicine at Mt. Sinai School of Medicine and Weill Medical College of Cornell University in New York. He has pioneered in new treatments for heart failure and helped establish new standards and methods for drug development. Dr. Franciosa authored over 250 publications and presented over 200 invited lectures worldwide. He serves on editorial boards and is an editorial consultant for several major medical journals. (This is me - Update Profile)
| 1995 - present | Owner Joseph A. Franciosa, MD, Consultant |
|---|---|
| 1991 - 1995 | Executive Director & Head, Medical Department Ciba-Geigy Pharmaceuticals |
| 1989 - present | Adjunct Professor of Medicine MOUNT SINAI SCHOOL OF MEDICINE |
| 1989 - present | Adjunct Professor of Medicine Weill Medical College of Cornell University |
| 1988 - 1990 | Vice President R&D Zambon Corp |
| 1986 - 1988 | Director, Cardiorenal Drugs, Clinical & Medical Af ICI Pharmaceuticals |
GLG Study Groups with Joseph Franciosa, MD(?)
| Study Group Name | Members |
|---|---|
| Physicians who Treat Hypertension (US) | 639 |
| Heart Failure Specialists (US) | 828 |
| BiDil Prescribers (US) | 55 |
| Physicians who Treat Hypercholesterolemia in the U.S. | 221 |
GLG NewsSM
Analyses by Joseph Franciosa, MD(?)
Implications: • The clinical trial experience with combination Altace plus hydrochlorothiazide (HCT) indicates safety and efficacy satisfactory for FDA approval. • The combination of ACE inhibitor and thiazide is old and ho-hum, and not as novel as newer combinations like Exforge (Novartis)....
Implications: Clinical trial results indicate that Nebivolol is a safe and effective antihypertensive agent.As a vasodilating beta-1 selective beta blocker, Nebivolol could compete successfully against long-acting carvedilol and metoprolol.To compete successfully, Nebivolol will have to gain approval...
Implications: Evidence suggests that statins produce potentially beneficial actions in heart failure, independent of lipid lowering. Clinical trials of statins in heart failure (independent of cholesterol levels) have been called for. Rosuvastatin (Crestor, AstraZeneca) failed to show...
Ximelagatran is the first orally active direct acting thrombin inhibitor. It is clearly easier to use and as effective as warfarin, the only other oral antithrombotic agent. Because of safety concerns, ximelagatran was not approved and was taken out of development. Many patients at risk of thromboses...
GLG InstituteSM Seminars with Joseph Franciosa, MD(?)
Recent Seminars
Request a project with Joseph Franciosa, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms